Published online May 6, 2021. doi: 10.12998/wjcc.v9.i13.3090
Peer-review started: October 15, 2020
First decision: January 24, 2021
Revised: January 28, 2021
Accepted: February 26, 2021
Article in press: February 26, 2021
Published online: May 6, 2021
Processing time: 187 Days and 7.8 Hours
Dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) is a rare subtype of DEB, characterized by recurrent pruritus of the extremities, pruritus papules, nodules, and mossy-like plaques. To date, fewer than 100 cases have been reported. We report a misdiagnosed 30-year-old man with sporadic late-onset DEB-Pr who responded well to tacrolimus treatment, thereby serving as a guide to correct diagnosis and treatment.
A 30-year-old man presented with recurrent itching plaques of 1-year duration in the left tibia that aggravated and involved both legs and the back. Examination revealed multiple symmetrical, purple, and hyperpigmented papules and nodules with surface exfoliation involving the tibia and dorsum of the neck with negative Nissl's sign, no abnormalities in the skin, mucosa, hair, or fingernail, and no local lymph node enlargement. Blisters were never reported prior to presentation. Serum immunoglobulin E level was 636 IU/mL. Clinical manifestations suggested DEB-Pr. Histological examination showed subepidermal fissure, scar tissue, and milia. Direct immunofluorescence showed no obvious abnormalities. However, we were unable to perform electron microscopy or genetic research following his choice. We treated him with topical tacrolimus. After 2 wk, the itching alleviated, and the skin lesions began to subside. No adverse reactions were observed during treatment.
Topical tacrolimus is a safe treatment option for patients with DEB-Pr and can achieve continuous relief of severe itching.
Core Tip: At present, fewer than 100 cases of dystrophic epidermolysis bullosa pruriginosa (DEB-Pr) have been reported. Delayed cases coupled with diversity of skin lesions make the diagnosis difficult. We report a late-onset case in which the patient did not develop the disease until the age of 30 years. There were no associated skin lesions in children and adulthood, and no family history was reported. The case was misdiagnosed many times, suggesting the importance of skin histopathology in diagnosing DEB-Pr. This patient was successfully treated with tacrolimus.